Hemorrhage / protease

Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

CROSS REFERENCE TO A RELATED APPLICATION This application is a National Stage Application of International Application Number PCT/EP2009/005465, filed Jul. 28, 2009; which claims priority to European Application No. 08013561.9, filed Jul. 28, 2008; which are incorporated herein by reference in their

Protease for activating clotting factor VII

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

The invention relates to a protease for activating the blood clotting factor VII, to a process for isolating it, detecting it and inactivating it, and to medicinal preparations which comprise this protease. BACKGROUND OF THE INVENTION The blood clotting system comprises two different, cascade-like

Trypsin-like serine protease inhibitors, and their preparation and use

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND OF THE INVENTION The invention relates to inhibitors of trypsin-like serine proteases of the general formula ##STR00001## which, besides plasmin, also inhibit plasma kallikrein, and to the preparation and use thereof as medicaments, preferably for the treatment of blood loss, especially

Trypsin-like serine protease inhibitors, and their preparation and use

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND OF THE INVENTION The invention relates to inhibitors of trypsin-like serine proteases of the general formula ##STR00001## which, besides plasmin, also inhibit plasma kallikrein, and to the preparation and use thereof as medicaments, preferably for the treatment of blood loss, especially

Trypsin-like serine protease inhibitors, and their preparation and use

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND OF THE INVENTION The invention relates to inhibitors of trypsin-like serine proteases of the general formula ##STR00001## which, besides plasmin, also inhibit plasma kallikrein, and to the preparation and use thereof as medicaments, preferably for the treatment of blood loss, especially

Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

FIELD OF THE INVENTION The invention is concerned with the use of the protease domain of human plasminogen activator, medicaments for the treatment of thromboembolic diseases, pharmaceutical compositions which contain, as an active component, said protein, and the uses thereof. BACKGROUND AND PRIOR

Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

FIELD OF THE INVENTION The invention is concerned with the use of the protease domain of human plasminogen activator, medicaments for the treatment of thromboembolic diseases, pharmaceutical compositions which contain, as an active component, said protein, and the uses thereof. BACKGROUND AND PRIOR

Protease inhibitor peptides

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND OF THE INVENTION The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which

Protease inhibitor peptides

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND OF THE INVENTION The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which

Protease inhibitor peptides

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND OF THE INVENTION The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which

Protease inhibitor peptides

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND OF THE INVENTION The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which

Protease for activating clotting factor VII

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

A protease for activating the blood clotting factor VII is described, which a) is inhibited by the presence of aprotinin, b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and c) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more

Crimean-Congo hemorrhagic fever virus vaccine

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

FIELD OF THE INVENTION This application relates generally to the field of viral disease, prophylaxis, and vaccination. More specifically, it provides a virus vaccine modeled on the etiologic agent for Crimean-Congo hemorrhagic fever. It was produced by reducing the deubiquinating and deISGylating

Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED AS AN ASCII TEXT FILE The Sequence Listing written in file U.S. Pat. No. 934,365_ST25.TXT, created on Jul. 7, 2014, 108,900 bytes, machine format IBM-PC, MS-Windows operating system, is hereby incorporated

Modified serpins for the treatment of bleeding disorders

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

SEQUENCE LISTING The instant application contains a Sequence Listing (.txt file named Sequence_Listing, having a date of May 4, 2018 and 63,944 bytes in size) which has been submitted in ASCII format via EFS-Web and is incorporated by reference herein. FIELD This invention relates to modified serpin

hemorrhage/protease

Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders

Protease for activating clotting factor VII

Trypsin-like serine protease inhibitors, and their preparation and use

Trypsin-like serine protease inhibitors, and their preparation and use

Trypsin-like serine protease inhibitors, and their preparation and use

Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases

Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases

Protease inhibitor peptides

Protease inhibitor peptides

Protease inhibitor peptides

Protease inhibitor peptides

Protease for activating clotting factor VII

Crimean-Congo hemorrhagic fever virus vaccine

Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus

Modified serpins for the treatment of bleeding disorders

O mais completo banco de dados de ervas medicinais apoiado pela ciência